Summit Therapeutics-JPM-2026-Investor-Deck.pdf

1、44th Annual J.P.MorganHealthcare ConferenceJanuary 12,2026BOB DUGGANChairman&Co-Chief Executive OfficerDR.MAKY ZANGANEHPresident&Co-Chief Executive OfficerForward Looking StatementAny statements in this presentation about the Companys future expectations,plans and prospects,including but not limited

2、 to,statements about the clinical and preclinical development of the Companys product candidates,entry into and actions related to the Companys partnership with Akeso Inc.,the Companys anticipated spending and cash runway,the therapeutic potential of the Companys product candidates,the potential com

3、mercialization of the Companys product candidates,the timing of initiation,completion and availability of data from clinical trials,the potential submission of applications for marketing approvals,the expected timing of BLA submissions or FDA decisions,potential acquisitions,statements about the pre

4、viously disclosed At-The-Market equity offering program(“ATM Program”),the expected proceeds and uses thereof,the Companys estimates regarding stock-based compensation,and other statements containing the words anticipate,believe,continue,could,estimate,expect,intend,may,plan,potential,predict,projec

5、t,should,target,would,and similar expressions,constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995.Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors,includi

6、ng the Companys ability to sell shares of our common stock under the ATM Program,the conditions affecting the capital markets,general economic,industry,or political conditions,including the effects of geopolitical developments,domestic and foreign trade policies,and monetary policies,the results of